CGM

Clear Guide Medical Receives FDA Clearance for CLEAR GUIDE SCENERGY™ Device for Transperineal Interventions

Retrieved on: 
星期二, 三月 5, 2024
ClinicalTrials.gov, Needle, FDA, Biopsy, Prostate, Patient, Sepsis, Diagnosis, CGM, Mayo Clinic, Clinical professor, CLEAR, Risk, Medical imaging

CLEAR GUIDE SCENERGY is a state-of-the-art system that delivers remarkable accuracy to enhance image-guided diagnostic and interventional procedures.

Key Points: 
  • CLEAR GUIDE SCENERGY is a state-of-the-art system that delivers remarkable accuracy to enhance image-guided diagnostic and interventional procedures.
  • While we always believed it would have a profound impact on cancer screenings, the clinical results for transperineal interventions have been truly remarkable," says Clear Guide Medical CMO Dr. Nick Karahalios.
  • "This latest FDA clearance exemplifies our commitment to advancing medical technologies for the benefit of patients and healthcare professionals," says Clear Guide Medical COO Patrick Duke.
  • For transperineal biopsy procedures, the CLEAR GUIDE SCENERGY-TP allows clinicians to guide biopsy needles through the perineal skin into the prostate, minimizing the risk of contamination associated with transrectal biopsies.

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
星期一, 二月 19, 2024
CE, Hospital, Com, Glucose meter, CGM, International Fair, MDR, Treatment, Booth, GS1, Conference, Emerging technologies, ATTD, GS, Prediabetes, Certification, GS2, Q&A, DSM-IV codes

LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024. The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference. According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes. SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.

Key Points: 
  • LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024.
  • The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference.
  • According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes.
  • SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
星期一, 二月 19, 2024
CE, Hospital, Com, Glucose meter, CGM, Multimedia, International Fair, MDR, Treatment, Booth, GS1, Conference, Emerging technologies, ATTD, GS, Prediabetes, Certification, GS2, Q&A, DSM-IV codes

LOS ANGELES, Feb. 18, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024. The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference. According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes. SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.

Key Points: 
  • LOS ANGELES, Feb. 18, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024.
  • The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference.
  • According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes.
  • SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time

Retrieved on: 
星期四, 二月 15, 2024
Diabetes, Health Technology, Health, Medical Devices, Eastern Time Zone, International, Publication, CGM, Webcast

Management will hold a conference call to review the Company’s fourth quarter and full year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

Key Points: 
  • Management will hold a conference call to review the Company’s fourth quarter and full year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.
  • The conference call will be concurrently webcast.
  • The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference.
  • To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 3711982, approximately ten to five minutes prior to start time.

Edgepark adding first-of-its kind, fully automated insulin delivery system to diabetes portfolio

Retrieved on: 
星期二, 二月 13, 2024
Diabetes, Dexcom, Urology, CGM, Stoma, RDN, LD, Physician, Sleep apnea, G6, AID, G7, Carb, Documentation, Health, Automation, Insulin, Patient, Disease, Type, Meal, Insurance, Pharmaceutical industry

TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio. The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses. Designed for anyone six years of age and older living with Type 1 diabetes, it eliminates the traditional manual work previously involved with using an insulin pump.

Key Points: 
  • TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio.
  • The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses.
  • "Edgepark is thrilled to offer the iLet as a first-of-its-kind device that uses automation to make diabetes simpler to navigate."
  • As with any insulin delivery system, users must also be able to load the insulin pump with insulin, insert an infusion set and troubleshoot when challenges occur.

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Retrieved on: 
星期二, 二月 13, 2024
Wearables, Mobile Technology, Apps, Applications, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Health, Tandem, Convatec, Dexcom, CGM, IPhone, Multimedia, G6, Compatibility, Control, Insulin, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.
  • View the full release here: https://www.businesswire.com/news/home/20240213214991/en/
    Tandem Mobi, the world’s smallest, durable insulin delivery system, now shipping in the United States.
  • The Tandem Customer Care team is available now to help determine eligibility and potential timing of pump shipments for customers.
  • People living with diabetes interested in the Tandem Mobi system can start the order process at: www.tandemdiabetes.com/mobi .

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Retrieved on: 
星期一, 二月 12, 2024
Software, Mobile, Wireless, Professional Services, Consumer Electronics, Apps, Applications, Medical Devices, Technology, Health Technology, Health Insurance, Insurance, Health, Diabetes, Blood glucose monitoring, MAC, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Retrieved on: 
星期一, 二月 12, 2024
Blood glucose monitoring, MAC, Diabetes, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
星期四, 二月 8, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Other Health, Biotechnology, Insulin, Dexcom, CGM, FDA, Investment, GAAP, ID, DXCM, Adjustment, Eastern Time Zone, International, Webcast, Table, Video game

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.
  • Fourth Quarter 2023 Financial Highlights:
    Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis.
  • Operating Income: GAAP operating income for the fourth quarter of 2023 was $216.9 million, compared to GAAP operating income of $125.4 million for the fourth quarter of 2022.
  • Non-GAAP operating income* for the fourth quarter of 2023 was $242.7 million, compared to non-GAAP operating income of $172.1 million for the fourth quarter of 2022.

CompuGroup Medical's ARIA RCM Services Ranked #1

Retrieved on: 
星期三, 二月 7, 2024
LIS, Software, EHR, ARIA, CGM, Feedback, Research, Environment, Health, Trust, RCM, Human, Nursing

AUSTIN, Texas , Feb. 7, 2024 /PRNewswire/ -- Today, CompuGroup Medical (CGM), a leading provider of ambulatory electronic health records (EHR), practice management software (PM), laboratory information systems (LIS), and revenue cycle management services (RCM) is pleased to announce that its ARIA RCM Services has been recognized as Best in KLAS® for Ambulatory RCM Services in the 2024 Best in KLAS: Software and Services Report .

Key Points: 
  • AUSTIN, Texas , Feb. 7, 2024 /PRNewswire/ -- Today, CompuGroup Medical (CGM), a leading provider of ambulatory electronic health records (EHR), practice management software (PM), laboratory information systems (LIS), and revenue cycle management services (RCM) is pleased to announce that its ARIA RCM Services has been recognized as Best in KLAS® for Ambulatory RCM Services in the 2024 Best in KLAS: Software and Services Report .
  • A CompuGroup Medical brand, ARIA provides end-to-end revenue cycle management services for medical groups and practices of all sizes across the United States.
  • "We are thrilled that our clients have recognized the outstanding quality of our revenue cycle management and credentialing services," said Derek Pickell, CEO, CompuGroup Medical US.
  • Customers who responded to KLAS surveys about ARIA RCM Services have highlighted strengths across multiple interview areas including the following interview responses:
    "Our manager at the firm is always available.